Is Lexicon Pharmaceuticals Inc (LXRX) overvalued? · rev $21.8M
Lexicon Pharmaceuticals Inc (LXRX) is a biotechnology company listed on US.
This page asks whether Lexicon Pharmaceuticals Inc (LXRX) looks expensive on cached numbers — not a short thesis.
Latest reported LXRX revenue for 2026-06-30 was $21.8M. Net income was -$32.8M. Revenue was up 3.3% from 2026-03-31 to 2026-06-30. LXRX currently screens at market cap $327.2M.
LXRX currently screens at market cap $327.2M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next LXRX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the LXRX stock page for the full model, not this heading.
Not investment advice.